Research from a medical testing company, London Medical Laboratory, finds that there is a “critical medication shortage” facing many diabetics in the UK.
The situation has been caused by people seeking to make off-label use of GLP-1 agonists approved and prescribed for diabetes.
The same active ingredient that is used in the diabetes medicine Ozempic (semaglutide) is also used in a different formulation approved for obesity, which is sold under the Wegovy brand.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze